NFKB1 and pancreas disorder: Research on pancreatic diseases has shown that NOX inhibitors reduced LPS-stimulated NF-κB P65 phosphorylation and IL-1β secretion in pancreatic stellate cells, thereby inhibiting pancreatic fibrosis [36].